Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) confirmed on Tuesday that it has completed the acquisition of Alesta Therapeutics, a clinical-stage biotechnology company focused on developing novel oral small-molecule therapies for underserved diseases.
This acquisition strengthens BioMarin's skeletal conditions portfolio, adding ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. ALE1 is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP.
Prior to the close of the transaction, Alesta spun out all non-ALE1 assets to a new entity. Alesta Therapeutics is now a wholly owned subsidiary of BioMarin.
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Enodia Therapeutics partners with Pfizer on Sec61-targeting drug development